It seems that the idea of recommending probiotics for “HIV+” people has become downright mainstream now. The following links were sent me by Tony Lance; they mention among other things dysbiosis and microbial translocation, which Tony had pointed to in his essay, cited on this blog nearly a decade ago (What really caused aids: slicing through the Gordian Knot).
“Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial” by Judit Villar-García et al.
“Microbes & HIV” by Jeannie Wraight
“STUDY: Probiotic could help prevent disorders in people with HIV” by Jeannie Wraight.
This mentions “A new study reported in the International Journal of Molecular Sciences”, presumably “Probiotics differently affect gut-associated lymphoid tissue indolamine-2,3-dioxygenase mRNA and cerebrospinal fluid neopterin levels in antiretroviral-treated HIV-1 infected patients: A pilot study” by Carolina Scagnolari et al. [Int. J. Mol. Sci. 2016, 17(10), 1639; doi:10.3390/ijms17101639] .
This article was in a special issue of IJMS, “Immuno- and Neuropathogenesis of HIV Disease: Mechanisms, Prevention, Treatment, and Cure” which included another pertinent piece:
“Impact of HIV infection and anti-retroviral therapy on the Immune profile of and microbial translocation in HIV-infected children in Vietnam” by Xiuqiong Bi et al. [Int. J. Mol. Sci. 2016, 17(8), 1245; doi:10.3390/ijms17081245] .
Neither of those sources mentions the probiotic Visbiome, referred to in Wraight’s article. However, the Visbiome website cites “Probiotic supplementation promotes a reduction in T-cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-1-positive patients” by Gabriella d’Ettorre et al. [Immunity, Inflammation and Disease, 2017; doi: 10.1002/iid3.160] whose Conclusions are worth quoting:
“These findings highlight the potential beneficial effects of probiotic supplementation for the reconstitution of physical and immunological integrity of the mucosal intestinal barrier in ART-treated HIV-1-positive patients”.